scholarly journals Exposure to inorganic particles in paediatric sarcoidosis: the PEDIASARC study

Thorax ◽  
2021 ◽  
pp. thoraxjnl-2021-217870
Author(s):  
Nadia Nathan ◽  
Marie-Emeline Montagne ◽  
Odile Macchi ◽  
Paul-André Rosental ◽  
Simon Chauveau ◽  
...  

Inorganic antigens may contribute to paediatric sarcoidosis. Thirty-six patients matched with 36 healthy controls as well as a group of 21 sickle-cell disease (SCD) controls answered an environmental questionnaire. Patients’ indirect exposure to inorganic particles, through coresidents’ occupations, was higher than in healthy and SCD controls (median score: 2.5 (0.5–7) vs 0.5 (0–2), p=0.003 and 1 (0–2), p=0.012, respectively), especially for construction, exposures to metal dust, talc, abrasive reagents and scouring products. Wood or fossil energies heating were also linked to paediatric sarcoidosis. This study supports a link between mineral environmental exposure due to adult coresident occupations and paediatric sarcoidosis.

Antioxidants ◽  
2019 ◽  
Vol 8 (8) ◽  
pp. 252 ◽  
Author(s):  
Cadiele Oliana Reichert ◽  
Carolina Garcia de Macedo ◽  
Débora Levy ◽  
Bruno Carnevale Sini ◽  
Andréia Moreira Monteiro ◽  
...  

(1) Background: Oxidative stress, chronic inflammation, vasoocclusion, and free iron are all features present in sickle cell disease. Paraoxonases (PON) are a family (PON-1, PON-2, PON-3) of antioxidant enzymes with anti-inflammatory action. Here, for the first time, we described PON-1 activities and PON-1, PON-2, PON-3 polymorphisms in patients with sickle cell disease, homozygous for HbSS, compared with healthy controls. (2) Methods: The groups were matched for age and gender. PON-1 activities (arylesterase and paraoxonase) were determined by enzymatic hydrolysis of phenylcetate and paraoxon, respectively. Polymorphisms were determined by Restriction Fragment Length Polymorphism- Polymerase Chain Reaction (RFLP-PCR). (3) Results: Plasma cholesterol and fractions, ApoA1 and ApoB levels were all decreased in sickle cell disease patients, while anti-oxidized low-density lipoprotein (LDL) antibodies and C-reactive protein were increased. Serum arylesterase activity was lower in sickle cell disease patients when compared with healthy controls. In patients, paraoxonase activity was higher in those with PON-1 RR Q192R polymorphism. In these patients, the increase of serum iron and ferritin levels and transferrin saturation were less pronounced than those observed in patients with QQ or QR polymorphism. No differences were observed with PON-1 L55M, and PON-2 and PON-3 polymorphisms. Multivariate regression analysis showed that transferrin and ferritin concentrations correlated with arylesterase and paraoxonase activities. (4) Conclusions: Both transferrin and ferritin were the main predictors of decreased arylesterase and paraoxonase activities in patients with sickle cell disease. LDL oxidation increased, and RR PON-1 Q192R polymorphism is likely to be a protective factor against oxidative damage in these patients.


Medicina ◽  
2019 ◽  
Vol 55 (5) ◽  
pp. 180
Author(s):  
Charles Antwi-Boasiako ◽  
Gifty Dankwah ◽  
Robert Aryee ◽  
Charles Hayfron-Benjamin ◽  
Alfred Doku ◽  
...  

Background and Objectives: Altered copper and zinc homeostasis may influence the antioxidant defense system and consequently lead to oxidative stress and associated complications in sickle cell disease (SCD) patients. Iron levels have been reported to increase in sickle cell patients due to frequent blood transfusion, chronic intravenous haemolysis and increased absorption of iron from the gastrointestinal tract. These elevated levels of iron may also lead to extensive oxidative damage. The current study evaluated serum levels of iron, copper and zinc in SCD patients and “healthy” controls. Materials and Methods: The study was a cross-sectional one, comprising 90 SCD patients with Haemoglobin SS and Haemoglobin SC genotypes and 50 HbAA “healthy” controls. Serum levels of iron, copper and zinc were measured using a Flame Atomic Absorption Spectrometer (Variant 240FS manufactured by VARIAN Australia Pty Ltd, VIC, Australia). Copper and zinc ratios were calculated and analyzed. Results: Serum levels of iron and copper were significantly elevated in the SCD patients, compared to their “healthy” counterparts (p < 0.001). These levels were further increased in patients with haemoglobin SS in vaso-occlusive crises (HbSS VOCs). Serum zinc levels were, however, significantly lower in the SCD patients, particularly during vaso-occlusion. The copper-to-zinc ratio was also found to be significantly higher in the SCD patients. Conclusion: Elevated copper-to-zinc ratio may be a biomarker of sickle cell oxidative stress and associated complications. The ratio may also be informative for the management of sickle cell oxidative burden. The significantly lower levels of zinc in the SCD patients may warrant zinc supplementation.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 538-538 ◽  
Author(s):  
Yihe Guo ◽  
Teresa Uy ◽  
Nancy Wandersee ◽  
J. Paul Scott ◽  
Hartmut Weiler ◽  
...  

Abstract The coagulation system is activated in sickle cell disease (SCD) and acute vaso-occlusion may heighten hypercoagulability. Protein C, a natural anticoagulant, has been reported to be low in individuals with SCD. Therefore, the natural anticoagulation pathway may be disrupted in SCD. The objective of this study is to more fully evaluate the protein C pathway in murine and human SCD by examining levels of: coagulation activation; protein C activity; thrombomodulin (TM); and endothelial protein C receptor (EPCR). In order to assess the level of activation of the coagulation system, we measured plasma thrombin/antithrombin (TAT) complex levels in humans and mice. TAT levels were elevated in 22 humans with SCD versus 9 healthy controls at baseline, and levels increased further in 15 individuals with SCD during acute vaso-occlusive events (5.6±1.2 vs. 2.4±0.2 vs. 9.2±1.8ug/L respectively, p=0.02). In order to study acute vaso-occlusive events in mice, we developed a model of acute vaso-occlusion by exposing Berkeley SCD mice to 3 hours of hypoxia (FI02 8–10%) followed by 2, 4, or 21 hours of reoxygenation in room air (HR2, HR4, HR21). In support of our human findings, TAT was elevated in SCD mice compared to HbA mice at baseline, and increased further in SCD mice exposed to HR2 (n=5–14 per group, p&lt;0.001). Assessment of protein C activity levels in plasma revealed that humans (n=8) with SCD have lower protein C activity levels than healthy controls (n=10) (78%±8.7% vs. 107%±5.3%, p=0.01). Additionally, we are the first to report that protein C activity levels decrease further during acute vaso-occlusive events (paired samples in 7 individuals, p=0.01). Another key protein of the PC pathway is TM, an endothelial-bound protein which activates protein C. TM is elevated in several chronic inflammatory diseases and acutely decreases in meningococcemia. We evaluated TM in mouse liver, an organ susceptible to vascular congestion, infarction, and inflammation in SCD mice. We first measured TM in mouse liver homogenates by ELISA. All SCD mice, at baseline and after HR, expressed elevated liver TM levels compared to HbA mice (n=6 per group, 1.7 to 2.9-fold increases in SCD livers, p&lt;0.05). Exposure to HR in SCD mice increased hepatic inflammation and ischemia and decreased hepatic TM levels compared to SCD mice at baseline (HR2 84%, HR4 60%, and HR21 85% of baseline SCD liver TM). In preliminary experiments, Western Blot analysis confirmed high TM expression in mouse SCD livers compared to HbA livers at baseline and after HR. Immunohistochemistry demonstrated widespread, increased TM staining in hepatic parenchymal vessels of SCD mice compared to HbA mice both at baseline and after HR, with decreased staining within mature infarcts. 4) Finally, we studied EPCR, a membrane-bound protein that binds circulating protein C and promotes both anti-thrombotic and anti-inflammatory functions. Similar to TM, immunohistochemical staining for EPCR was more prominent in hepatic parenchymal vessels of SCD mice compared to HbA mice at baseline and after HR (preliminary studies, n=3 per group). In summary, these data confirm that SCD is a prothrombotic state and suggest that the protein C pathway is altered in SCD. TAT levels are elevated in human and murine SCD, and increase further during vaso-occlusion, illustrating that SCD is a hypercoagulable state. Protein C activity levels are low in human SCD and decrease further during vaso-occlusive events, suggesting that protein C may be consumed both chronically and acutely. In SCD mice at baseline, elevated expression of TM and EPCR suggests that there may be a chronic, compensatory up-regulation of these proteins in SCD. Finally, an acute consumptive process could account for the transient, decreasing trend of these natural anticoagulant proteins in SCD mice after exposure to HR. Thus, targeted administration of activated protein C may provide a novel therapy to minimize tissue injury during acute vaso-occlusive events in SCD.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 2572-2572
Author(s):  
Erfan Nur ◽  
Willem Mairuhu ◽  
Dees P. Brandjes ◽  
Ton van Zanten ◽  
Bart J. Biemond ◽  
...  

Abstract Abstract 2572 Poster Board II-549 Introduction: Sickle cell disease (SCD) is commonly manifested through skeletal involvement. Besides the characteristic acute musculoskeletal pain, SCD is also associated with chronic skeletal complications such as osteopenia and osteoporosis. During bone resorption, the collagen cross-links pyridinoline (PYD) and deoxypyridinoline (DPD) are released into circulation with subsequent urinary excretion. Measurements of urinary PYD and DPD could serve as valuable tools in detecting osteoporosis in the follow-up of SCD patients but perhaps also in determining the severity of bone infarction during painful crises. Therefore we compared urinary concentrations of PYD and DPD of SCD patients during asymptomatic state and painful crisis with those of race- and age-matched healthy controls. Methods: Urinary concentrations of PYD and DPD, adjusted for urine creatinine, were measured in SCD patients both during asymptomatic state (n=38) and painful crisis (n=27) and healthy controls with normal HbA hemoglobin (n=25) using high performance liquid chromatography (HPLC). Results: PYD and DPD concentrations were higher in asymptomatic SCD patients compared to controls ((54.8 (41.5–68.6) vs. 44.1 (37.7–49.9),P=0.005 and 11.6 (9.3–15.2) vs. 8.5 (6.8–10.4),P=0.004 respectively), with further increments during painful crisis (63.3 (51.8–76.0),P=0.041 and 15.3(13.0–21.5),P=0.003 respectively). In the asymptomatic patients levels of PYD and DPD were significantly correlated to the degree of hemolysis. Conclusion: In sickle cell patients bone resorption is increased and significantly correlated to the degree of hemolysis, compatible with their susceptibility to osteopenia and osteoporosis. Measurement of pyridinoline and deoxypyridinoline could have additional value as biomarkers of osteoporosis in SCD. During painful crises a further increment in bone degradation was observed. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 764-764
Author(s):  
Abdoul Karim Dembele ◽  
Patricia Hermand-Tournamille ◽  
Florence Missud ◽  
Emmanuelle Lesprit ◽  
Malika Benkerrou ◽  
...  

Abstract Sickle cell disease (SCD) is a severe hemoglobinopathy due to abnormal hemoglobin S (HbS). Although red blood cell dysfunction is at the core of the SCD pathophysiology, several studies have highlighted the important role of inflammatory cells like neutrophils. One of the most serious complications of SCD is cerebral vasculopathy (CV), due to the occlusion of one or more intracranial or cervical arteries. In 1998, the STOP study demonstrated that monthly blood transfusions could reduce the risk of stroke by 90% in children with CV. However, there is large heterogeneity in the evolution of CV under chronic transfusion, sometimes requiring exchange transfusion (ET) program for years without succeeding in healing the CV. The aim of the study is to investigate the impact of long-term transfusion program on neutrophil dysfunction, in order to understand if persistent inflammation could contribute to the non-healing of CV despite HbS permanently below 40%. In SCD children undergoing ET program for at least 1 year, we analysed i)the phenotype of neutrophils with 8 markers of activation/adhesion/ageing, ii)the plasmatic levels of elastase, witnessing the NETose activity of neutrophils, and iii)the ex-vivo adhesion of neutrophils on activated endothelial cells. One hundred and two SCD children with an ET transfusion program for at least 6 months because of CV were included in the study. ET session, carried out every 5 weeks and most of the time by erythrapheresis, reached their biological objectives with a mean HbS rate after ET session of 14.1%, and 35.4% before the next ET session, which means that these patients globally live at an average HbS level of 24% for at least 1 year. We managed to limit iron overload with a mean ferritinemia of 207 µg/L in the whole cohort. Despite these satisfactory results in terms of HbS reduction, the efficiency in curing the CV was modest in accordance with the previously described efficiency of ET program in SCD children: after a mean ET program duration of 4.4 years only 22% of them had an improvement of their CV since the beginning of the ET program, while 60% of them had a stagnation of their CV, and 18% of them worsened their vascular lesions. Considering inflammatory parameters, the patients had persistence of high leukocytosis and high neutrophils count (respective mean of 9810 G/L and 5742 G/L), significantly not different of neutrophils count before inclusion in the ET program. In a random subgroup of 20 patients, we analysed neutrophils phenotype, NETose and endothelial adhesion and compared them to healthy controls and SCD children without ET, treated or not with Hydroxyurea (HU). Overall, we observed as expected an activated, aged and adherent profile of neutrophils from untreated SCD children compared to healthy controls, characterized by an overexpression of CD18/CD11b (p=0,03), CD18/CD11a (p=0,02), CD162 (p=0,01), CD66a (p=0,01) and the ageing markers CD184 high/CD62Llow (p=0,04) as well as a higher plasmatic level of elastase (p=0. 01) and higher adhesion of neutrophils to endothelial cells. All these parameters were alleviated in SCD patients treated with HU. In SCD patient undergoing ET program, we found a similar profile of activated neutrophils to that of untreated SCD patients with a similar expression of activation molecules, high level of elastase and the same increase of neutrophils adhesion to endothelial cells compared to controls, witnessing a persistence of chronic inflammation despites years of ET. Overall, our study highlights that the replacement of sickle red blood cells, even for years, is not sufficient to reverse the deleterious inflammatory phenotype of neutrophils. Given the major role of inflammation in endothelial dysfunction, these could contribute to the persistence of CV in a majority of patients despite efficient ET programs. This raises the question of systematically combining ET program with anti-inflammatory treatment such as HU or P-selectin inhibitors in children with CV. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2017 ◽  
Vol 130 (Suppl_1) ◽  
pp. 972-972
Author(s):  
Lena Vaclavu ◽  
Lena Vaclavu ◽  
Henri JMM Mutsaerts ◽  
Esben Thade Petersen ◽  
Ed T VanBavel ◽  
...  

Abstract Introduction: Sickle Cell Disease (SCD) is frequently complicated by stroke. Although transcranial Doppler effectively identifies children at risk for stroke, adult patients do not benefit from this test. In SCD, chronic hemolytic anemia leads to cerebral vasodilation, elevated cerebral blood flow (CBF) and subsequently, impaired cerebrovascular reserve (CVR) capacity. CVR represents the maximum increase in CBF in response to metabolic stressors. CVR mapping is a promising imaging biomarker for stroke risk assessment, potentially identifying patients with preclinical hemodynamic impairment. Our laboratory performs CVR mapping by measuring CBF prior to and following maximum cerebral vasodilation with acetazolamide (ACZ). The primary aim of this study was to quantitatively assess CVR in adult patients with SCD compared to healthy controls. Methods: Adult SCD patients (HbSS/HbSβ0) were recruited for this IRB-approved study with ACZ-induced vasodilation and venous blood sampling. Patients with a history of clinically overt stroke were excluded. Controls were selected from patients' friends and family members without SCD and matched on age, sex, and race. The following MRI images were acquired at 3T (Philips Healthcare, Best, NL): time of flight MRA for visualization of major cerebral vessels, T2 FLAIR for manual segmentation of white matter hyperintensities (WMHs), and pseudo-continuous arterial spin labeling (ASL) for CBF assessment. CBF was measured at baseline and 10min post ACZ (16mg/kg intravenous infusion over 3min). MRI images were processed with the ExploreASL toolbox, to obtain registered maps of quantified CBF and CVR (% change in CBF). We measured T1blood in each subject to improve quantification accuracy as these values can differ in SCD. Group comparisons were performed using non-parametric two-sample tests. Correlations were characterized by Spearman's rho (ρ). P&lt;0.05 was considered significant. Median values with interquartile range (IQR) are reported for non-normally distributed variables, otherwise mean and standard deviation are reported. Results: 30 patients with SCD (mean age 33±12y,19M) and 11 controls (mean age 37±15y, 6M) were included in this cross-sectional controlled cohort study. Mean hemoglobin levels in patients with SCD were 8.8±1.4 g/dL and in healthy controls were 13.7±1.3 g/dL. Patients with SCD had higher baseline CBF compared to healthy controls (median 73(IQR:25) vs 42(IQR:6) mL/100g/min, p&lt;0.001, F1a). CBF was inversely related to hemoglobin (ρ=-0.84, p&lt;0.001, F1b). ACZ elicited an increase in CBF(p&lt;0.001) which was similar in magnitude in both groups (patients 29±16, controls 35±11, mL/100g/min, F1c), resulting in a lower mean CVR in patients compared to controls (41±24% vs 81±27%, p&lt;0.001, F1d). Baseline CBF predicted CVR (ρ=-0.68, p&lt;0.001, F1e). WMHs were present in both groups, and WMH volume correlated with age (ρ = 0.54, p&lt;0.001). There were no statistical associations between WMH volume and CVR (ρ = -0.15, p=0.4) or CBF(ρ = 0.02, p=0.9), however, two patients with the largest WMH volume (&gt;6 mL) had the lowest CVR (&lt;20%). Discussion: This study shows that regional CVR can be measured using ASL-MRI with ACZ challenge. ACZ was well-tolerated and elicited a robust cerebrovasodilatory response in both groups. However, the relative increase in oxygen delivery (CVR) was much lower in SCD patients, which suggests that patients with SCD have nearly maximal cerebrovascular dilation at baseline. Our data suggest that chronic vasodilation due to anaemia has let to outward remodelling of vessels in adult patients, permitting a larger vascular bed to compensate their anemia. Our premise is that resting O2 delivery is normal in SCD patients; we showed that increasing CBF overcomes severe anemia. However, high resting CBF limits the brain's ability to recruit additional O2 under times of stress. SCD patients have many transient interruptions in O2 delivery including aplastic crisis, splenic sequestration and sleep apnea, as well as metabolic stressors such as fever, sickle cell crisis, infection, and seizure. While baseline CBF predicted global CVR, ASL provides information regarding regional O2 delivery that may offer insight into distribution of ischemic white matter damage. Further study is needed to determine the impact of blood transfusions and hydroxyurea on CVR and whether there is a critical CVR threshold that predicts stroke risk. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 4837-4837
Author(s):  
Osama Mukarram ◽  
Gian Lima ◽  
Samuel Crooks ◽  
Min Jung Kim ◽  
Agnes S Kim

Background: Sickle Cell Disease (SCD) is characterized by chronic anemia and recurrent ischemia-reperfusion episodes that contribute to high output heart failure. The effects of SCD on the heart are significantly underrecognized. Methods: SCD patients who underwent echocardiography between March 2016 and March 2018 were retrospectively analyzed. Patients with reduced Left Ventricular Ejection Fraction (LVEF) and valvular heart disease were excluded. Cardiac chamber size, systolic and diastolic function parameters, and LV and RV strain were compared between hemoglobin SS (most severe form of SCD) and SC (less severe form) subtypes and against healthy controls. Wilcoxon signed rank test was used for statistical analysis. Results: SS patients (n = 48, mean age 31.9) had lower mean hemoglobin 8.9 g/dl vs 11.3 g/dl (p < 0.001) and hematocrit 25.8% vs 31.4% (p = 0.008) and higher LDH 437 IU/L vs 258 IU/L (p < 0.001) compared to SC patients (n = 11, mean age 34.4). Both SS and SC patients had worse diastolic function compared to healthy controls: higher E velocity 98.9 cm/s (SS), 86.4 cm/s (SC), 76.4 cm/s (control) (SS vs control, p < 0.01; SC vs control, p < 0.05) and higher E/A ratio 1.76 (SS), 1.59 (SC), 1.15 (control) (SS vs control, p < 0.001; SC vs control, p < 0.01). SS patients had larger indexed left atrial volume compared to SC patients (39.3 ml/m2 vs 28.4 ml/m2, p = 0.007). There was no significant difference in LVEF, left ventricular global longitudinal strain, or right ventricular strain between SS and SC subtypes compared to healthy controls. Furthermore, SS patients with a serum LDH > 500 IU/L had higher E/e' ratio (11.3 vs 7.2, p=0.001) and larger indexed Left Ventricular End Diastolic Volume (LVEDVi) (80.8 ml/m2 vs 53.4 ml/m2, p=0.002) compared to SS patients with LDH < 500 IU/L. Conclusion: SCD genotype adversely determines the degree of cardiac dysfunction in patients with SCD. LVEDVi, left atrial size, E velocity, E/A ratio, and E/e' ratio may serve as useful echocardiographic parameters to follow in this patient population. Serum LDH has been associated with poor clinical outcomes in patients with SCD, and as demonstrated by our study, it also portends worsening cardiac function in this population at high risk for heart failure. Figure Disclosures No relevant conflicts of interest to declare.


2016 ◽  
Vol 4 (5) ◽  
Author(s):  
Olufunmilayo E. Adejumo ◽  
Taiwo R. Kotila ◽  
Adeyinka G. Falusi ◽  
Boladale O. Silva ◽  
Jacinta N. Nwogu ◽  
...  

2019 ◽  
Vol 37 (2) ◽  
pp. 123-128
Author(s):  
Marie L. Suarez ◽  
Judith M. Schlaeger ◽  
Veronica Angulo ◽  
David A. Shuey ◽  
Jesus Carrasco ◽  
...  

Objectives: Sickle cell disease (SCD) is a serious illness with disabling acute and chronic pain that needs better therapies, but insufficient patient participation in research is a major impediment to advancing SCD pain management. The purpose of this article is to discuss the challenges of conducting an SCD study and approaches to successfully overcoming those challenges. Design: In a repeated-measures, longitudinal study designed to characterize SCD pain phenotypes, we recruited 311 adults of African ancestry. Adults with SCD completed 4 study visits 6 months apart, and age- and gender-matched healthy controls completed 1 visit. Results: We recruited and completed measures on 186 patients with SCD and 125 healthy controls. We retained 151 patients with SCD with data at 4 time points over 18 months and 125 healthy controls (1 time point) but encountered many challenges in recruitment and study visit completion. Enrollment delays often arose from patients’ difficulty in taking time from their complicated lives and frequent pain episodes. Once scheduled, participants with SCD cancelled 49% of visits often because of pain; controls canceled 30% of their scheduled visits. To facilitate recruitment and retention, we implemented a number of strategies that were invaluable in our success. Conclusion: Patients’ struggles with illness, chronic pain, and their life situations resulted in many challenges to recruitment and completion of study visits. Important to overcoming challenges was gaining the trust of patients with SCD and a participant-centered approach. Early identification of potential problems allowed strategies to be instituted proactively, leading to success.


2014 ◽  
Vol 138 (5) ◽  
pp. 678-683 ◽  
Author(s):  
Salah Al-Humood ◽  
Rajaa Zueriq ◽  
Lama Al-Faris ◽  
Rajaa Marouf ◽  
Fahd Al-Mulla

Context.—Vascular occlusion in sickle cell disease causes increased levels of plasma cell-free DNA as a result of cell death and tissue damage. Objectives.—This study investigates plasma cell-free DNA concentrations in sickle cell disease patients, and aims at exploring the significance of plasma cell-free DNA as a potential biomarker in predicting its complications. Design.—Plasma cell-free DNA levels were measured using real-time quantitative polymerase chain reaction to quantitatively measure β-globin gene in blood samples from 57 sickle cell disease patients with acute vaso-occlusive crisis, 42 patients in steady state, 16 individuals with sickle cell trait, and 40 healthy controls. Results.—Plasma cell-free DNA level was significantly elevated in samples from patients with acute vaso-occlusive crisis when compared with those in steady state (P = .002), and was significantly higher both in crisis and in steady state when compared with individuals with sickle cell trait and healthy controls (P &lt; .001). There was no difference in cell-free DNA levels between individuals with sickle cell trait and healthy controls. There was no association between plasma cell-free DNA levels and various clinical complications of sickle cell disease and comorbidity. Conclusions.—Plasma cell-free DNA, as quantified by polymerase chain reaction amplification of the β-globin and human telomerase reverse transcriptase genes, is increased in sickle cell disease patients in vaso-occlusive crisis and in steady state compared with individuals with sickle cell trait and healthy controls, and may be used as a tool to diagnose and monitor the sickle cell crisis and differentiate post–packed red cell transfusion sickle cell disease patients from individuals with sickle cell trait.


Sign in / Sign up

Export Citation Format

Share Document